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Abstract: Breast cancer is the first common cause of cancer-related death in women worldwide. Since the malig-
nancy and aggressiveness of breast cancer have been correlated with the presence of breast cancer stem cells, 
the establishment of a disease model with cancer stem cells is required for the development of a novel therapeutic 
strategy. Here, we aimed to evaluate the availability of cancer stem cell models developed from mouse induced 
pluripotent stem cells with the conditioned medium of different subtypes of breast cancer cell lines, the hormonal-
responsive T47D cell line and the triple-negative breast cancer BT549 cell line, to generate in vivo tumor models. 
When transplanted into the mammary fat pads of BALB/c nude mice, these two model cells formed malignant 
tumors exhibiting pronounced histopathological characteristics similar to breast cancers. Serial transplantation of 
the primary cultured cells into mammary fat pads evoked the same features of breast cancer, while this result was 
perturbed following subcutaneous transplantation. The tumors formed in the mammary fat pads exhibited immune 
reactivities to prolactin receptor, progesterone receptor, green florescent protein, Ki67, CD44, estrogen receptor 
α/β and cytokeratin 8, while all of the tumors and their derived primary cells exhibited immunoreactivity to estrogen 
receptor α/β and cytokeratin 8. Cancer stem cells can be developed from pluripotent stem cells via the secretory 
factors of cancer-derived cells with the capacity to inherit tissue specificity. However, cancer stem cells should be 
plastic enough to be affected by the microenvironment of specific tissues. In summary, we successfully established 
a breast cancer tumor model using mouse induced pluripotent stem cells developed from normal fibroblasts without 
genetic manipulation.
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Introduction
Cancer is the most serious disease in the world, 
and the rate of incidence of new cases is still 
high. Breast cancer (BC) is the first common 
cause of cancer-related death in women world-
wide. The crude rates per 100,000 population 
of BC occurrence in 2020 are estimated to be 
45 in Asia, 137 in Europe, 151 in North America, 
and 28 in Africa according to WHO 2020. BC 
represents approximately 25% of all types of 
cancer [1]. BC is characterized by distinct stag-
es, from atypical ductal hyperplasia (ADH) and 
ductal carcinoma in situ (DCIS) to invasive 
breast cancer [2]. Several studies have report-
ed that the cause of tumors, including BC, is 
attributed to the presence of small numbers of 
heterogeneous cell populations. These small 
cell populations are called cancer stem cells 
(CSCs), which represent approximately 1 to 5% 
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of all cells in tumor tissue [3]. CSCs are charac-
terized by their potential for self-renewal, differ-
entiation and tumorigenesis [4, 5], resulting in 
increasing rates of tumor progression [6], cell 
mobility [7, 8], cell invasion and metastasis [9, 
10] together with the formation of blood ves-
sels for angiogenesis. Recently, the role of 
CSCs in BC has been clarified by the expression 
of some cell surface markers on cells isolated 
from tumors [3]. However, the analyses of CSCs 
in tumor tissues have not been efficient and 
practical due to their low abundance.
Previously, our group successfully developed 
unique models of CSCs from induced pluripo-
tent stem cells (iPSCs), which were developed 
from normal embryonic fibroblasts, in the pres-
ence of conditioned medium (CM) from a can-
cer cell culture mimicking the tumor microenvi-
ronment [11]. Using this model, we found that 
CSCs may generate cancer-associated cells, 
such as vascular endothelial cells, cancer-
associated fibroblasts (CAFs) [12], tumor-asso-
ciated adipocytes and tumor-associated mac-
rophages (TAMs) [13], which form a part of the 
tumor microenvironment (TME) [14]. Thus, 
CSCs appear to be supported and maintained 
in heterogeneous tumor tissues, creating a 
niche that maintains the balance between self-
renewal and differentiation [15]. During the 
course of the studies, we successfully estab-
lished two different tissue-specific models, a 
pancreatic ductal adenocarcinoma CSC model 
[16] and a liver CSC model [17], both of which 
were converted from mouse iPSCs (miPSCs) in 
the presence of CM from pancreatic cancer 
cells and liver cancer cells, respectively, devel-
oped via the effects of tissue-specific factors in 
vivo. In conclusion, the TME can be considered 
a mixture of microenvironments that are gener-
ated by CSCs on the one hand and by adjacent 
normal tissues on the other hand.
In the present study, we aimed to establish an 
in vivo breast cancer model of CSCs converted 
from miPSCs with CM from different subtypes 
of BC cell lines via transplantation by compar-
ing the phenotypes that may be plastic depend-
ing on the microenvironment, such as the mam-




The CSC models miPS-T47Dcm and miPS-
BT549cm cells, were previously prepared by 
our group [12]. The human breast cancer cell 
line T47D, which was derived from the pleural 
effusion of a ductal carcinoma found in the 
mammary gland of an elderly human patient, 
and the cell line BT549, which was derived 
from triple-negative breast cancer, were 
obtained from Riken Cell Bank, Japan. The nor-
mal mouse mammary epithelial cell line 
NMuMG was a kind gift from Dr. David Salomon 
under an MTA of the National Cancer Institute, 
MD. The cells were cultured in RPMI-1640 
medium (WAKO, Japan) supplemented with 
10% fetal bovine serum (FBS) (Gibco®, Life 
Technologies™, USA) and 100 U/ml penicillin/
streptomycin (P/S) (Nacalai Tesque, Japan). The 
cells were cultured and maintained in a 37°C 
incubator with 5% CO2 until reaching 80% con-
fluence. To prepare the CM, the medium was 
supplemented with 5% FBS, and after 48 h, the 
medium was collected, centrifuged for 10 min 
at 1000 rpm and then filtered through a 0.22 
μm filter (Millipore, Ireland). The CM was stored 
at -20°C until use. The miPSCs (iPS MEF-Ng-
20D-17, Riken Cell Bank, Japan) [18] were 
maintained in DMEM supplemented with 15% 
FBS, 0.1 mM MEM with nonessential amino 
acids (Wako, Japan), 2 mM L-glutamine, 100 U/
ml P/S (Nacalai Tesque, Japan), 0.1 mM 2-mer-
captoethanol (Sigma-Aldrich, USA), and 1000 
U/ml leukemia inhibitory factor (WAKO, Japan) 
on a feeder layer of mitomycin-treated mouse 
embryonic fibroblast (MEF) cells (Reprocell, 
Japan) seeded at 5×104 cells in a 60-mm dish 
(TPP, Switzerland). The miPSCs were seeded at 
5×105 cells on MEFs coated with 0.1% gelatin 
(Sigma, USA) and maintained under the same 
conditions.
Animal experiments
Four-week-old female BALB/c-nu/nu mice were 
purchased from Charles River, Japan. The 
experimental animals were divided into the s.c. 
and MFP groups. For transplantation, 1×106 
cells were suspended in 100 μl of Hank’s bal-
anced salt solution (Gibco®, Life Technologies™, 
USA) and injected dorsally into the s.c. tissue or 
into one of the fourth pair (4G) of MFP. The 
experimental protocol is summarized in Figure 
1A. In the primary (P) tumors, miPS-T47Dcm 
and miPS-BT549cm cells were injected into s.c. 
tissue or MFPs. The tumors obtained from the 
s.c. group were named Ts.c./Bs.c., while the 
tumors obtained from the MFP group were 
named Tm1/Bm1. Mice were sacrificed after 
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approximately 4 weeks when the size of the 
tumor reached approximately 1 cm in diameter. 
Immediately after sacrifice, tissues from Ts.c./
Bs.c. and Tm1/Bm1 tumors were directly trans-
planted into s.c. tissue to obtain tumors nam- 
ed Tds.c./Bds.c. and Tdm/Bdm. P1 cultures 
from Tm1/Bm1 tumors were prepared as 
described by Chen et al. (2012), and the 
obtained cells, named miPS-T47DcmP1MFP 
and miPS-BT549cmP1MFP, were injected into 
the MFPs to yield the secondary tumors, named 
Tm2/Bm2. After 4 weeks, the mice were sacri-
ficed, and P cultures from Tm2/Bm2 tumors 
were prepared according to Chen et al. (2012). 
The obtained cells, miPS-T47DcmP2MFP and 
miPS-BT549cmP2MFP, were injected into the 
MFPs to yield tertiary tumors, Tm3/Bm3. The 
present study was approved by the Animal Care 
Use Committee of Okayama University under 
IDs OKU-2020382 and OKU-2020652.
Histopathological analysis
For the histopathological analysis, tumors were 
immediately removed from mice, fixed in 10% 
neutral formalin (Wako, Japan) for 24 h, and 
Figure 1. A. Schematic drawing of the preparation of primary cells. The first stage: miPS-T47DcmP1sc, miPS-
BT549cmP1sc, miPS-T47DcmP1sc/sc, miPS-BT549cmP1sc/sc, miPS-T47DcmP1MFP, miPS-BT549cmP1MFP, 
miPS-T47DcmP1MFP/sc and miPS-BT549cmP1MFP/sc cells from the tumors developed from the transplantation 
of miPS-T47Dcm and miPS-BT549cm cells in BALB/c-nu/nu mice. The second stage of primary cells is the P culture 
of the Tm2/Bm2 tumors. The third stage of primary cells is the P culture of the Tm3/Bm3 tumors. Each stage of 
primary cells is surrounded by red broken squares. Ts.c./Bs.c. and Tm1/Bm1 are the primary tumors (blue broken 
circles). Tds.c./Bds.c., Tm2/Bm2 and Tdm/Bdm are the secondary tumors (yellow broken circles). Tm3/Bm3 is the 
tertiary tumor (gray broken circles). B. The macroscopic features of the Tm1 tumor transplanted into the MFPs. The 
border of the tumor was ill defined (red line) with a firm consistency that was too hard (left). The cut surface shows 
hemorrhage and necrotic areas (middle). The base appears indurated and infiltrating (right).
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embedded in molten paraffin wax (Wako, Ja- 
pan). Then, the paraffin blocks were cut by us- 
ing an automatic rotary microtome (HistoCore 
AUTOCUT, Leica, Germany) with a 5 µm thick-
ness. Then, sections were stained with hema-
toxylin (Merck, Germany) and counterstained 
with alcoholic 0.5% Eosin Y (Wako, Japan). 
Sections were examined by using an Olympus 
FSX100 microscope (Olympus, Tokyo, Japan), 
and images were captured with an FSX100 digi-
tal camera (Olympus) and processed with FSX-
BSW version 3.2. software (Olympus) on 10x 
NA0.40 and 20x NA0.95 objective lenses.
Immunohistochemical (IHC) analysis
Paraffin sections with a thickness of 5 µm were 
stained for IHC analysis according to the proce-
dures of the ABC Vectastain kit with an Elite 
anti-rabbit IgG antibody (Vector Laboratories, 
USA). Protein expression was detected by using 
DAB substrates (Vector Laboratories, USA) and 
counterstained with hematoxylin. The primary 
antibodies used in this study were as follows: 
anti-mouse estrogen receptor beta (ERβ) rabbit 
polyclonal antibody (1:50, ab3576, Abcam, 
UK), anti-mouse progesterone receptor (PR) 
rabbit polyclonal antibody (1:100, ab63605, 
Abcam, UK), anti-mouse prolactin receptor 
(PRL-R) rabbit monoclonal antibody (1:50, 
ab170935, Abcam, UK), anti-mouse CD44 rab-
bit polyclonal antibody (1:200, ab24504, 
Abcam, UK), anti-mouse Ki67 rabbit polyclonal 
antibody (1:100, ab66155, Abcam, UK), and 
anti-mouse green florescent protein (GFP) rab-
bit monoclonal antibody (1:500, #2956, Cell 
Signaling Technology, USA). The negative con-
trol sections were prepared identically to all 
other slides, but the primary antibody was re- 
placed with an isotype rabbit IgG (Wako, Japan). 
Slides were examined, and images were taken 
as described above on an LCACHN40xPHP 
NA0.55 objective lens.
Immunofluorescence analysis
For the immunofluorescence analysis, paraffin 
sections with a 5 µm thickness were dewaxed, 
rehydrated and treated by antigen retrieval (tri-
sodium citrate dihydrate). The sections were 
incubated with the following primary antibodies 
overnight at 4°C: anti-mouse estrogen receptor 
α (ERα) mouse monoclonal antibody (1:50, 
sc-8005; Santa Cruz Biotechnology, CA) and 
anti-mouse cytokeratin 8 (CK8) mouse mono-
clonal antibody (1:50, sc-8020; Santa Cruz 
Biotechnology, CA). Then, the slides were incu-
bated with Alexa Fluor® 594-labeled goat anti-
mouse IgG (1:1000, ab150116; Abcam, UK). 
Nuclei were counterstained by mounting 
with antifade mounting medium containing 
4,6-diamidino-2-phenylindole (DAPI; Vector lab-
oratories). The negative control sections were 
prepared identically to all other slides, but the 
primary antibody was replaced with an isotype 
mouse IgG (Wako, Japan) (Figure 12). Slides 
were examined, and images were taken 
by using an Olympus FSX100 microscope 
(Olympus, Tokyo, Japan) on an LCACHN40xPHP 
NA0.55 objective lens. The florescence filters 
used to capture the florescence digital images 
included a green filter (U-MWIBA3), red filter 
(U-MWIG3) and blue filter (U-MNUA2).
Immunocytochemical analysis
The cells were seeded at 1×105 cells/well in a 
12-well plate that contained a gelatin-coated 
coverslip in each well. The plate was incubated 
at 37°C with 5% CO2 until cells were attached. 
Then, the medium was carefully aspirated, and 
the wells were washed 3 times with PBS. Then, 
the cells were fixed with 4% paraformaldehyde 
(Nacalai Tesque, Japan) for 20 min. The cells 
were permeabilized with 0.1% Triton X-100 
(Nacalai Tesque, Japan) in PBS and blocked in 
1% bovine serum albumin (Sigma, USA) fol-
lowed by several washes with PBS and incuba-
tion with the primary anti-mouse ERα rabbit 
monoclonal antibody (1:1000, ab32063; 
Abcam, UK) and anti-mouse PR rabbit poly-
clonal antibody (1:500, ab63605; Abcam, UK) 
overnight at 4°C. At that time, the cells were 
washed with PBS and incubated with Alexa 
Fluor 555®-labeled goat anti-rabbit IgG (H+L) 
(1:1000, A21428; Invitrogen Thermo Fisher 
Scientific, USA) for 1 h at room temperature. 
Then, slides were mounted with antifade 
mounting medium containing DAPI (Vector 
Laboratories). Slides were examined, and imag-
es were taken as described above.
Protein extraction and western blotting
Total protein of cells or tissues was extracted 
with lysis buffer (1 M Tris-HCl, pH 8, 5 M NaCl, 
10% Triton, 0.4 M EDTA and Mill Q H2O) contain-
ing a proteinase inhibitor cocktail (225955-11, 
Nacalai Tesque, Japan). The proteins were sub-
jected to 12.5% SDS-PAGE, and then proteins 
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were transferred to polyvinylidene difluoride 
membranes (Millipore-Merck, Germany). The 
membranes were then blocked in 5% skim milk 
by shaking for 1 h at room temperature, and 
then the membranes were incubated with the 
primary anti-mouse β-actin monoclonal anti-
body (1:1000, 010-27841; Wako, Japan), anti-
mouse ERβ rabbit polyclonal antibody (1:1000, 
ab3576; Abcam, UK), anti-mouse ERα mouse 
monoclonal antibody (1:200, sc-8005; Santa 
Cruz Biotechnology, CA) and anti-mouse CK8 
mouse monoclonal antibody (1:200, sc-8020; 
Santa Cruz Biotechnology, CA) overnight at 
4°C followed by incubation with horseradish 
peroxidase-conjugated anti-rabbit/mouse IgG 
(1:1000, #7074s/#7076s, Cell Signaling Tech- 
nology, MA) as the secondary antibody for 1 h 
at room temperature. Immunoreactivity on the 
membrane was developed, and images were 
captured by WSE-6100H-ACP LuminoGraph I 
and processed with ImageSaver6 version 2.7.2 
software (ATTO Bioscience and Biotechnology; 
Tokyo, Japan).
RNA isolation and reverse transcription quanti-
tative PCR (RT-qPCR)
Total RNA of cells or tissues was isolated with 
TRIzol (Life Technologies, USA) following the 
manufacturer’s protocol. The extracted RNA 
was treated with DNase I (Promega, Nasison, 
W.I., USA). One microgram of RNA was reverse 
transcribed with the GoScript™ Reverse Tr- 
anscription System (Promega, Nasison, W.I, 
USA). RT-qPCR was performed with Light Cycler 
480 SYBR green I Master Mix (Roche Dia- 
gnostics GmbH, Germany) on a Light Cycler 
480 II (Roche Diagnostics GmbH, Germany) fol-
lowing the manufacturer’s instructions. All 
primers used in this study were designed with 
bioinformatics tools, such as BLAST (NCBI, 
Bethesda, MD, USA) and Primer3 tools (Table 
1), and synthesized by Eurofins Genomics, 
Japan.
Image analysis
Digital IHC and Western blotting images were 
analyzed by a semiquantitative scoring system 
(Fiji-ImageJ software, Java-based application 
for analyzing images) (http://imagej.nih.gov/
ij/). The percentage of the stained area (area 
fraction) was determined by measuring six ran-
domly photographed high-power fields 20× 
[19]. Additionally, this program was applied to 
compare the density of bands of different 
immunoreactive proteins on Western blot.
Statistical analysis
All data obtained are expressed as the mean ± 
standard deviation (mean ± SD). The signifi-
cance between different groups was evaluated 
by using one-way ANOVA.
Results
Focusing on the pathological signatures 
of breast cancer including ERα/β, PR and PRL-
R, we investigated the characteristics of 
Ts.c./Bs.c., Tm1/Bm1, Tds.c./Bds.c., Tdm/
Bdm, Tm2/Bm2 and Tm3/Bm3 tumors derived 
from CSC models of miPS-T47Dcm and miPS-
BT549cm cells and their primary cultures in 
this study (Figure 1A).
Macroscopic features of the tumors
The macroscopic features of the developed 
tumors indicated that these tumors were malig-
nant when transplanted into either the MFPs or 
s.c. tissue. A representative tumor is shown in 
Figure 1B. The border of the tumor was ill 
defined with a firm consistency that was not 
too hard. The cut surface appears with hemor-
rhage and necrotic areas as well as an indurat-
ed and infiltrating base.
Morphological characteristics of the tumors as 
BC
The tumors showed different histopathological 
features under microscopic examinations. 
Those of Ts.c./Bs.c. and Tm1/Bm1 (Figures 2, 
3). Pronounced characteristics of histopatho-
logical malignancies, such as invasive lobular 
carcinoma (ILC) like structures with small round 
nuclei, inconspicuous nuclei and scant cyto-
plasm, were observed in the Tm1 tumor of 
miPS-T47Dcm cells that were implanted into 
the MFPs (Figure 2A). Tumors of miPS-T47Dc-
mP1 cells transplanted into the MFPs, which 
formed Tm2 tumors, resembled ADH, solid 
DCIS and high mitotic activity with a gastroin-
testinal structure (Figure 2B). In the tertiary 
Tm3 tumor in which miPS-T47DcmP2 cells were 
transplanted into the MFPs, duct ectasia with 
fatty necrosis, adenosis, active mitogenic cells 
and lymph node metastasis with a focal legion 
and disrupted capsule like structures were 
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Figure 2. Histopathological observations in the sections of tumors, Tm1, 
Tm2, Tm3, Ts.c., Tdm and Tds.c. obtained from miPS-T47Dcm cells trans-
planted in BALB/c-nu/nu mice. (A-D, F) Tumors developed in MFP (E, G) 
Tumors developed in s.c. Arrows indicate ILC (A) ADH and gastrointestinal 
structure (B) duct ectasia with fatty necrosis and adenosis (C, lymph node 
metastasis (LN) with focal legion and disrupted capsule (D) adenosis (E) 
ILC (F) active mitogenic cells with necrotic areas (G) like structures, Hema-
toxylin and Eosin, scale bar = 129 µm at 10× magnification, 64 µm at 20× 
magnification.
found (Figure 2C, 2D). Adenosis was observed 
only in mouse Ts.c. tumors from miPS-T47Dcm 
cells transplanted into s.c. tissue (Figure 2E). 
These results were compared with those from 
tumors developed from tumor tissue speci-
mens. The Tdm tumor of miPS-T47DcmP1 was 
directly transplanted into s.c. tissue (miPS-
T47DcmP1MFP/sc) showed DCIS as well as ILC 
like structures (Figure 2F), while active mito-
genic cells and necrotic areas 
were recognized in the Tds.c. 
tumor, which was directly tr- 
ansplanted from a Ts.c. tumor 
(Figure 2G).
In the Bm1 tumor in which 
miPS-BT549cm cells were tr- 
ansplanted into the MFPs, 
resembled high-grade DCIS 
with central comedo necrosis, 
solid DCIS with a completely 
filled duct characterized by 
enlarged pleomorphic nuclei, 
fibrocystic dilated ducts and 
adenosis were observed (Fi- 
gure 3A). The similar charac-
teristic of ILC with small nuclei 
and cytoplasmic vacuolation 
surrounded by fibers was found 
in the Bm2 tumor of miPS-
BT549cmP1 cells transplanted 
into the MFPs (Figure 3B), 
while medullary carcinoma 
with pleomorphic nuclei sur-
rounded by fibers and infiltrat-
ed lymphatic cells like struc-
ture was detected in the Bm3 
tumor of miPS-BT549cmP2 
cells transplanted into the 
MFPs (Figure 3C). In the Bs.c. 
tumor of miPS-BT549cm cells 
transplanted into s.c. tissue, 
developed lobular carcinoma 
in situ was observed (Figure 
3D). It should be noted that 
the allograft model of miPS-
BT549cmP1 tumor the Bdm 
tumor specimen was trans-
planted into s.c. tissue (miPS-
BT549cmP1MFP/sc) resem-
bled ADH and ILC, while the 
Bds.c. tumor transplanted fr- 
om s.c. tissue to s.c. tissue 
(miPS-BT549cmP1sc/sc) sho- 
wed infiltrated ductal carcinoma like structures 
(Figure 3E, 3F).
Tumors obtained from mice transplanted with 
miPSCs on one side of the 4G of the MFPs 
showed different germ layers of a teratoma, 
such as skin and hair (ectoderm in origin), con-
sisting of keratinized stratified squamous epi-
thelium (Figure 3G), while tumors obtained 
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from mice in which miPSCs were transplanted 
into s.c. tissue showed gastrointestinal struc-
tures (endoderm in origin) lined with simple 
columnar epithelium in the intestine as well as 
nonkeratinized stratified squamous epithelium 
identical to those in the esophagus (Figure 3H).
The characteristics of all the tumors are sum-
marized in Table 2. Both miPS-T47Dcm and 
tumors transplanted into the MFPs from both 
miPS-T47Dcm and miPS-BT549cm cells (Figure 
4). The Bdm tumor showed strong immunoreac-
tivity for PR (Figure 5C), while immunoreactivity 
was moderate in the Bm1 tumor of miPS-
BT549cm cells transplanted into the MFPs, 
and low immunoreactivity was low in the Ts.c. 
tumor of miPS-T47Dcm cells transplanted into 
s.c. tissue (Figure 4B). On the other hand, 
Figure 3. Histopathological observations in the sections of tumors, Bm1, 
Bm2, Bm3, Bs.c., Bdm and Bds.c. were developed from miPS-BT549cm 
cells transplanted in BALB/c-nu/nu mice and benign teratoma developed 
from miPSCs. (A-C, E, G) Tumors developed in MFP (D, F, H) Tumors devel-
oped in s.c. Arrows indicate high grade DCIS with comedo necrosis and solid 
DCIS* with completely filled duct with enlarged and pleomorphic nuclei (A), 
ILC (B), medullary carcinoma (C), lobular carcinoma in situ (D), ILC (E), infil-
trated ductal carcinoma (F), hair follicles (G), and gastrointestinal structures 
(H) like structures, Hematoxylin and Eosin, scale bar = 129 µm at 10× mag-
nification, 64 µm at 20× magnification. 
miPS-BT549cm cells exhibited 
more malignancy and aggres-
siveness when transplanted 
into the MFPs than into s.c. tis-
sue. However, miPS-T47Dcm 
cells did not exhibit BC charac-
teristics when transplanted 
into s.c. tissue as the primary 
and secondary generations of 
Ts.c./Bs.c. and Tds.c./Bds.c 
tumors. Even Tm3 tumors, 
which were the tertiary genera-
tion of cells transplanted into 
the MFPs, lost BC characteris-
tics and exhibited metastasis 
into lymph nodes, which are 
often observed in malignant 
BC. Hence, we focused on the 
primary tumors, Tm1/Bm1, 
transplanted into the MFPs, in 
the following analyses to evalu-
ate the differences between 
MFP- and s.c.-microenviron- 
ments comparing the MFP 
tumors with tumors transplant-
ed into s.c. tissue, Ts.c/Bs.c. 
and Tdm/Bdm, so that the 
effect of MFP microenviron-
ment could be distinguished 
from that of s.c. microen- 
vironment.
Markers in the tumors cor-
related with the microenviron-
ment
To address the presence of 
hormone receptors in the mod-
els, immunostaining was per-
formed in Tm1/Bm1, Ts.c./
Bs.c. and Tdm/Bdm tumors. 
The immunoreactivity to ERα/ 
β, PR, PRL-R, Ki67, CK8 and 
CD44 was evaluated (Figures 
4, 5). Immunoreactive ERβ 
was detected in Tm1/Bm1 
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Figure 4. IHC analysis of primary Tm1/Bm1 and Ts.c./Bs.c. tumors transplanted into the MFPs and s.c. tissue, 
respectively. A. Immunoreactivity to ERβ, PR, PRL-R, Ki67 and CD44 is shown in paraffin sections of Tm/Bm1 and 
Ts.c./Bs.c. tumors derived from miPS-T47Dcm and miPS-BT549cm cells. Scale bar = 64 µm at 20× magnification. 
B. Percentage of the immunoreactive area (mean ± SD) of ERβ, PR, PRL-R, Ki67 and CD44 in the different experi-
mental groups. Each bar in the graphs represents the average of six readings (mean ± SD). Significance compared 
with tumors derived from miPSCs transplanted into the MFPs. *P<0.05, **P<0.01, ***P<0.001.
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PRL-R was strongly detected in the membranes 
and cytoplasm of all ducts in the Tdm tumor 
(Figure 5C). Simultaneously, moderate immu-
noreactivity for PRL-R was found in the Tm1/
Bm1 tumors of both miPS-T47Dcm and miPS-
BT549cm cells transplanted into the MFPs, 
while strong immunoreactivity for CD44 was 
observed in the Bm1 and Tdm tumors (Figure 
4B). The immunoreactivity for GFP was relative-
ly weak overall (Figure 5B, 5D). The prolifera-
tion marker Ki67 was recognized as moderately 
immunoreactive in the Tm1 tumor of miPS-
T47Dcm cells transplanted into the MFPs 
(Figure 4B). The immunoreactivities for the 
markers in the tumors (Figures 4B, 5C) are 
summarized in Table 3. In summary, Tm1/Bm1, 
Ts.c./Bs.c. and Tdm/Bdm tumors exhibited 
comparably strong immunoreactivity for ERβ, 
while Ts.c./Bs.c. tumors exhibited comparably 
weaker immunoreactivity for PR, PRL-R, Ki67 
and CD44 than Tm1/Bm1 and Tdm/Bdm 
tumors. The MFP, as the tumor microenviron-
ment, appears more effective in exerting mam-
mary tumor-like features than s.c. tissue. 
Considering the results obtained from Tdm/
Bdm tumors, these features appeared to be 
fixed in the primary tumors and sustained in 
the secondary tumors even when the microen-
vironment was changed to s.c. tissue.
Immunofluorescent staining of ERα and CK8 in 
the Tm1/Bm1 and Ts.c./Bs.c. tumors was 
assessed (Figure 6). The immunoreactivity for 
ERα was detected in the cytoplasm and mem-
brane in different sections of the Tm1/Bm1, 
Ts.c./Bs.c., Tdm/Bdm tumors (Figures 6A and 
7A), while it was negative in the teratoma 
derived from miPSCs transplanted into the 
MFPs (Figure 6A). The merged pattern of ERα 
and GFP was yellow, indicating that ERα was 
localized in the cytoplasm in the Tm1 tumor of 
miPS-T47Dcm cells. Immunoreactivity for CK8 
was detected in each tumor allograft model 
(Figures 6B and 7B). However, the colocaliza-
tion of CK8 and GFP was evident in the Bm1 
tumor of miPs-BT549cm cells transplanted into 
the MFPs, exhibiting a yellow pattern when 
merged (Figure 6B). The immunoreactivity for 
GFP and cytoplasmic localization were con-
firmed at the same time as the reference undif-
ferentiated marker.
Markers in primary cells correlated with the 
tumor microenvironment
Subsequently, we assessed the immunoreac-
tivity for ERα and PR in the primary cells from 
Tm1/Bm1 and Ts.c./Bs.c. tumors (Figures 8 
and 9). Both ERα and PR were observed in the 
nuclei and cytoplasm of miPS-T47Dcm, miPS-
BT549cm, miPS-T47DcmP1MFP, miPS-T47Dc-
mP1sc, miPS-BT549cmP1MFP and miPS-BT- 
549cmP1sc whereas T47D cells were put for 
the reference of immunoreactivity. The miPS-
T47DcmP1MFP cells appeared more differenti-
ated (reddish in color), while miPS-T47DcmP1sc 
cells appeared undifferentiated (yellowish in 
color) when GFP and ERα were merged. Bas- 
ed on the immunoreactivity for ERα, miPS-
BT549cmP1MFP cells appeared more undiffer-
entiated than miPS-BT549cm P1sc cells when 
GFP and ERα were merged.
Based on the immunoreactivity for PR, the 
localization of PR and cell differentiation were 
not very different between miPS-T47DcmP1M-
FP cells and miPS-T47DcmP1sc cells. On the 
other hand, miPS-BT549cmP1MFP cells app- 
eared to be more differentiated (reddish in 
color), while miPS-BT549cmP1sc cells app- 
eared to be undifferentiated (green in color) 
when GFP and ERα were merged. PR was local-
ized to the nuclei in both miPS-BT549cmP1M-
FP cells and miPS-BT549cmP1sc cells, where 
its immunoreactivity was recognized. In sum-
mary, the MFP appears to be a more effective 
microenvironment to evoke the differentiated 
mammary phenotype than s.c. tissue.
Markers in the tumors correlated with BC
We further assessed the expression of ERα, 
ERβ and CK8 using Western blotting (Figure 
10A, 10B). The expression of ERα, ERβ and 
Figure 5. IHC analysis of Tm1/Bm1 and Tdm/Bdm tumors sections transplanted into MFP and s.c. tissue, respec-
tively. A. Immunoreactivity to ERβ, PR, PRL-R, Ki67 and CD44 is shown in paraffin sections of Tdm/Bdm, both 
derived from Tm1 and Bm1 tumors transplanted into s.c. tissue. B. The immunoreactivity of GFP in all Tm1/Bm1, 
Tdm/Bdm and miPSCs tumor in MFP. Scale bar = 64 µm at 20× magnification. C, D. Percentage of the immunoreac-
tive area (mean ± SD) of ERβ, PR, PRL-R, Ki67, CD44 and GFP expression in the different experimental groups. Each 
bar in the graphs represents the average of six reading (mean ± SD). Significant compared with tumors derived from 
miPSCs transplanted into the MFPs. *P<0.05, **P<0.01, ***P<0.001.
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Figure 6. Immunofluorescence analysis of primary Tm1/Bm1 tumors transplanted into the MFPs and Ts.c./Bs.c. 
tumors transplanted into s.c. tissue. Immunoreactivity to both ERα and CK8 was detected in paraffin sections from 
Tm1/Bm1 and Ts.c./Bs.c. tumors derived from miPS-T47Dcm and miPS-BT549cm cells. A. ERα immunoreactivity 
(red) was observed in the cytoplasm and membrane of tumor cells. B. CK8 immunoreactivity (red) was detected in 
the cytoplasm and perinucleus of tumor cells. Scale bar = 32 µm at 40× magnification.
Figure 7. Immunofluorescence analysis of paraffin sections from Tdm and Bdm tumors. The immunoreactivity of 
both ERα and CK8 were detected in theses sections that derived from Tm1 and Bm1 tumors transplanted into s.c. 
tissue. A. ERα immunoreactivity (red) was observed in the cytoplasm and membrane of the tumor sections. B. CK8 
immunoreactivity (red) was detected in the cytoplasm and perinuclear of tumor sections. Scale bar = 32 µm at 40× 
magnification.
CK8 was approximately 3- to 5-fold higher in 
the Tm1 and Ts.c. tumors of miPS-T47Dcm cells 
transplanted into the MFPs and s.c. tissue than 
those of NMuMG cells, while the expression of 
ERβ was approximately 3.8- and 4-fold higher 
only in the Bm1 and Bs.c. tumors of miPS-
BT549cm cells transplanted into the MFPs and 
s.c. tissue than those of NMuMG cells, respec-
tively. However, in the Tds.c./Bds.c. and Tdm/
Bdm tumors, where mitogenic figures and inva-
sion were observed (Figure 10B), the expres-
sion of CK8 as well as ERα and ERβ was signifi-
cant (Figure 10C). CK8 immunoreactivity was 
high in the Ts.c. and Tm1 tumors of miPS-
T47Dcm cells due to the presence of invasive 
mitogenic cells and ILC while its immunoreac-
tivity was only slight in the Bs.c. and Bm1 
tumors of miPS-BT549cm cells because no 
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Figure 8. Immunocytochemical analysis of ERα in T47D, miPS-T47Dcm, miPS-T47DcmP1MFP miPS-T47DcmP1sc, 
miPS-BT549cm, miPS-BT549cmP1MFP and miPS-BT549cmP1sc cells. ERα immunoreactivity (red) was detected in 
the nuclei, cytoplasm and membrane of different cells. Scale bar = 32 µm at 40× magnification.
invasion was detected in these tumors. From 
these results, in vivo transplantation into ei- 
ther the MFPs or s.c. tissue appear to enhance 
the characteristics of BC. However, treatment 
with the CM of T47D cells was more effective 
than those of BT549 cells in inducing BC 
characteristics.
Stemness markers in developed tumors
The expression of the stemness markers 
NANOG, SOX2, KLF4 and OCT3/4 was assess- 
ed in the Ts.c./Bs.c., Tm1/Bm1 and Tdm/Bdm 
tumors by RT-PCR (Figure 11). In the Ts.c. and 
Tm1 tumors of miPS-T47Dcm cells, the stem-
ness markers were highly expressed. The 
expression of NANOG was enhanced in both 
miPS-T47Dcm and miPs-BT549cm cells. The 
expression of KLF4 was distinguished in the 
Tm1 tumor of miPS-T47Dcm cells, while it was 
suppressed in miPS-T47Dcm cells, miPS-
BT549cm cells, the Ts.c. tumor of miPS-T47Dcm 
cells, and the Bm1 tumor of miPS-BT549cm 
cells. Alternatively, the expression of SOX2 
was enhanced in both Ts.c./Bs.c tumors. The 
expression of OCT3/4 was detected in all 
tumors and cells. These results indicated that 
the Ts.c./Bs.c. and Tm1/Bm1 tumors of both 
miPS-T47Dcm and miPS-BT549cm cells con-
tained undifferentiated cells.
Discussion
BC is typically heterogeneous, probably due to 
the presence of undifferentiated cancer cells 
with stemness (so-called CSCs), which exhibit 
variously differentiated phenotypes depending 
on the microenvironment. In this study, we eval-
uated the phenotypes of CSCs that were previ-
ously prepared from miPSCs by treatment with 
the CM of the human breast cancer cell lines 
T47D and BT549. These two different subtypes 
of breast carcinoma-derived cells were select-
ed to evaluate the potential to confer the differ-
ent characteristics of breast carcinomas to 
CSCs.
The histopathological characteristics of the 
tumors transplanted into the MFPs were com-
pared to those transplanted into s.c. tissue. 
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Figure 9. Immunocytochemistry analysis of PR in T47D, miPS-T47Dcm, miPS-T47DcmP1MFP, miPS-T47DcmP1sc, 
miPS-BT549cm, miPS-BT549cmP1MFP and miPS-BT549cmP1sc cells. PR immunoreactivity (red) was detected in 
the nuclei and cytoplasm of different cells. Scale bar = 32 µm at 40× magnification.
Two different CSC models of miPS-T47Dcm and 
miPS-BT549cm cells provided different sub-
types of tumors, including DCIS, invasive ductal 
carcinoma (IDC) and ILC, depending on the site 
of transplantation, while BC can be categorized 
into more than 21 different histological types 
based on the architecture, morphology and 
growth patterns of cells [20]. ILC is the second 
most common type of BC after IDC, represent-
ing the most aggressive pathological pheno-
type [21-23]. ILC is observed in the range of 
approximately 10 to 15% of all types of breast 
cancer. The presence of ILC makes the diagno-
sis significantly more precise [24]. In some 
reports, the diagnosis of ILC was characterized 
by a large tumor size and positive expression of 
both ER and PR [25-29]. This agrees with our 
observation of ILC in this study. The tumors in 
the first to third stages of miPS-BT549cm cells 
showed high aggressiveness when transplant-
ed into either the MFPs or s.c. tissue. This 
aggressiveness is much higher than that of 
miPS-T47Dcm cells. Although miPS-BT549cm 
cells exhibited aggressiveness similar to triple-
negative breast carcinoma, miPS-BT549cm 
CSCs are not derived from triple-negative carci-
noma. This result indicated that CM derived 
from BT549 cells, which are derived from a tri-
ple-negative subtype, was not the critical deter-
minant that induced the identical features of 
cancers in miPSCs affected by CM. Although 
the effect of the microenvironment on cancer 
initiation should be investigated further at this 
point, our results suggest that the MFPs may 
allow the TME to serve as a platform of tumor 
growth, as summarized in Table 2. Both miPS-
T47Dcm and BT549cm cells developed malig-
nant and aggressive tumors when transplanted 
into the MFPs, while miPS-T47Dcm cells did not 
develop malignant and aggressive tumors 
when transplanted into s.c. tissue. This means 
that the malignancy of tumors depends not only 
on the characteristics of CSCs but also on the 
TME.
The crucial role of the MFPs in the development 
of tumors has been described in different stud-
ies following the transplantation of carcinoma-
derived cells into the MFPs. The tumor cells 
transplanted into the 4G of MFPs exhibited dis-
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Figure 10. Immunoreactive BC markers in different types of cells and tissues. A, B. Western blot analysis of ERα, 
ERβ and CK8. C, D. Densitometric analysis of the western blots with ImageJ. C. NMuMG cells, miPS-T47Dcm cells, 
Tm1 and Ts.c. tumors of miPS-T47Dcm cell transplants, miPS-BT549cm cells, and Bm1 and Bs.c. tumors of miPS-
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BT549cm cell transplants (from left to right). D. NMuMG cells, Tdm, Tds.c., Bdm and Bds.c. tumors from miPS-
T47DcmP1MFP, miPS-T47DcmP1sc, miPS-BT549cmP1MFP and miPS-BT549cmP1sc tumors (from left to right). 
The density of each band was normalized to that of β-actin. Each bar in the graphs represents the average of three 
readings (mean ± SD). *P<0.05, **P<0.01, ***P<0.001.
Figure 11. The expression of stemness markers analyzed by RT-qPCR. Expression of stemness markers NANOG, 
KLF4, SOX2 and OCT3/4 in miPSCs, miPS-T47Dcm cells, tumors Tm1, Tdm, Ts.c., Tds.c. of miPS-T47Dcm cell trans-
plants, miPS-BT549cm cells, tumors Bm1, Bdm, Bs.c., Bds.c. of miPS-BT549cm cell transplants (from left to right). 
Each bar in the graphs represents the average of three reactions (mean ± SD). The significance was compared with 
the expression in miPSCs. *P<0.05, **P<0.01, ***P<0.001.
tinguished growth from those transplanted into 
other sites, such as the perirenal region, meso-
metrium, and s.c. tissue [30]. Another study 
demonstrated the extensive growth of tumors 
when breast cancer-derived adenocarcinoma 
cells were coinjected with adipose tissue from 
mice into the MFPs and s.c. tissue. Since this 
growth was clearly distinguished from that of 
the xenografts of cells without adipocytes, the 
role of adipose tissues from the MFPs was 
found to be significantly important for encour-
aging tumor growth [31]. Adipocytes are one of 
the stromal cells rich in breast tissue that affect 
the growth of CSCs by secreting various cyto-
kines, chemokines, growth factors and other 
factors [32-34]. The effects of the microenvi-
ronment of the MFPs on growth kinetics, tumor 
histology and drugs have recently been com-
pared to those of patient-derived xenografts in 
mice [35]. The tumors in all tested cases were 
found to be more significantly affected in the 
MFPs than in s.c. tissue. Considering that the 
adipose tissue of the MFPs is enriched with 
saturated fatty acids and mono- and polyun-
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Figure 12. Immunofluorescence analysis of isotype control in different groups by using primary isotype mouse IgG 
antibody. The immunoreactivity of isotype control was detected in paraffin sections of tumors miPSCs/MFP, Tm1, 
Bm1, Ts.c., Bs.c., Tdm and Bdm. Scale bar = 32 µm at 40× magnification.
Table 1. Sequences of primers used in the study
Gene name Accession No. Forward Primer 5’→3’ Reverse Primer 5’→3’
GAPDH NM_008084 AACGGCACAGTCAAGGCCGA ACCCTTTTGGCTCCACCCTT
NANOG NM_028016.3 AGGGTCTGCTACTGAGATGCTCTG CAACCACTGGTTTTTCTGCCACCG
KLF4 NM_010637.3 GCGAACTCACACAGGCGAGAAACC TTATCGTCGACCACTGTGCTGCTG
SOX2 NM_011443.4 TTGCCTTAAACAAGACCACGAAA TTGCCTTAAACAAGACCACGAAA
OCT3/4 NM_013633.3 TCTTTCCACCAGGCCCCCGGCTC TGCGGGCGGACATGGGGAGATCC
saturated fatty acids are depleted, probably 
due to lipolytic agents, the oxidative metabo-
lism of estrogen could enhance the hydroxyl-
ation of estrone to hydroxylated forms [36]. The 
release of fatty acids from adipocytes of the 
MFPs is altered by the presence of the epithe-
lium [37]. In this context, the coexistence of the 
MFPs and tumor-derived epithelium can have a 
characteristic influence on tumor growth [38].
The obtained phenotypes of miPSC-derived 
CSCs were characterized by mammary tumor-
related markers such as ERα/β, PR, PRL-R and 
CK8 together with common carcinoma markers 
such as Ki67 and CD44 and stemness markers 
such as NANOG, SOX2, OCT3/4 and KLF4. 
These features are rather characteristic of the 
Tm1/Bm1 tumors from both miPS-T47Dcm and 
miPS-BT549cm cells, indicating the supporting 
effects of the MFPs (Table 3). One of the impor-
tant features in the growth of BC can be 
explained by the enhanced expression of cyclin 
D1 by the binding of ERα to the promoter [39], 
while the expression of ERβ suppressed by the 
progression of BC [40]. Nevertheless, many 
studies have indicated a significant role for ERβ 
in mammary tumorigenesis [41]. Progesterone 
reacts with PR within cells in an endocrine man-
ner, which induces the activation of mammary 
stem cells, which were believed to induce the 
migration of primary tumor cells [42]. Prolactin 
stimulates cell proliferation and migration in 
breast tumorigenesis by binding to PRL-R, 
which is believed to indicate the risk of BC [43-
45]. The expression of CK8 is hypothesized to 
be related to ILC [46-49]. Collectively, the 
detected markers in this study could indicate 
that miPS-T47Dcm and miPS-BT549cm cells 
are miPSC-derived CSCs.
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Table 2. Morphological characteristic of tumors obtained by transplantation
CSCs miPS-T47Dcm miPS-BT549cm
Site Tumor BC type Other type Malignancy Tumor BC type Other type Malignancy
MFP Tm1 ILC - +++ Bm1 DCIS, solid DCIS - ++
Tm2 ADH, solid DCIS - ++ Bm2 ILC - +++
Tm3 - Duct ectasia, fatty necrosis, adenosis, lymph node metastasis +* Bm3 Medullary carcinoma - ++
s.c. Tdm DCIS, ILC - +++ Bdm ADH, ILC - +++
Ts.c. - Adenosis - Bs.c. Lobular carcinoma in situ - ++
Tds.c. - Mitogenic cells, necrotic area + Bds.c. Infiltrated ductal carcinoma - ++
+, moderate; ++, middle; +++, high; +*, moderate with metastasis. Tm1; miPS-T47Dcm MFP, Tm2; miPS-T47DcmP1MFP, Tm3; miPS-T47DcmP2MFP, Tdm; Tm1direct s.c. transplantation, Ts.c.; miPS-T47Dcm s.c., 
Tds.c.; Ts.c. direct s.c. transplantation, Bm1; miPS-BT549cm MFP, Bm2; miPS-BT549cmP1MFP, Bm3; miPS-BT549cmP2MFP, Bdm; Bm1direct s.c. transplantation, Bs.c.; miPS-BT549cm s.c., Bds.c.; Bs.c. 
direct s.c. transplantation.
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CD44 is a marker of CSCs, and its expression is 
often high in stem cells associated with CSCs 
that undergo epithelial-to-mesenchymal transi-
tion [50]. The immunohistochemical expres-
sion of CD44 has been demonstrated to be 
higher in in situ tumors than in invasive tumors 
[51], which agrees with our results. Similarly, in 
our previous study, we detected the expression 
of the CD44+/CD24-low population in miPS-
T47Dcm and miPS-BT549cm cells by flow 
cytometry, but its expression was higher in pri-
mary cells from tumors transplanted into s.c. 
tissue [12]. This finding may be related to 
the enhanced expression of CD44 in miPS-
BT549cm cells in the Bm1 tumor, indicating the 
effect of the MFPs integrated with the charac-
teristics of the CSCs themselves. Moreover, 
activated CAFs also enhance the expression of 
stemness markers such as CD44, OCT3/4, 
NANOG and KLF4 in CSCs [52], agreeing with 
our observation in miPSC-derived CSCs (Figure 
11).
In conclusion, we demonstrated that CSCs con-
verted from normal miPSCs under the microen-
vironment of BC provided different malignant 
tumorigenic subtypes of BC. The microenviron-
ment of the MFPs was simultaneously shown to 
be more effective than that of s.c. tissue to 
develop the subtypes related with BC. In sum-
mary, we successfully established a breast 
cancer tumor model using mouse induced plu-
ripotent stem cells developed from normal 
fibroblasts without genetic manipulation.
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